SRNE - Sorrento Therapeutics, Inc.
| Previous Close | 3.490 |
| Open | 3.480 |
| Bid | 3.570 x 1300 |
| Ask | 3.580 x 2200 |
| Day's Range | 3.460 - 3.640 |
| 52 Week Range | 2.150 - 10.650 |
| Volume | 363,723 |
| Avg. Volume | 1,600,341 |
| Market Cap | 397.349M |
| Beta (3Y Monthly) | 3.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.67 |
- GlobeNewswire•5 days ago
Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million
Sorrento Therapeutics, Inc. (SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150 million. The financing is being provided by funds and accounts managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm.
- GlobeNewswire•7 days ago
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
Sorrento Therapeutics, Inc. (SRNE) ("Sorrento") announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases (HITM-SURE) clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen–positive (CEA+), unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases (HITM) method.
- GlobeNewswire•12 days ago
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc. (SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manufactured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study. This study is the first US-based clinical trial targeting CD38 using an autologous CAR-T cell therapy.
- GlobeNewswire•19 days ago
Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Motley Fool•last month
Here's Why Sorrento Therapeutics Fell 20.7% in September
A recently announced debt financing won't dilute shareholders, but it still has Wall Street worried.
- Kiplinger•last month
10 Growth Stocks to Buy With Monster Potential
The stock market - especially growth stocks - is at an interesting inflection point as we enter the final quarter of 2018. On the one hand, the Standard & Poor's 500-stock index recovered from a tumultuous midyear with a 7% third-quarter gain that marked its best quarterly performance since 2013. On the other, interest-rate worries have sent a quick scare into the markets, and riskier, growth-oriented equities have suffered a bit of a pullback. Still, corporate earnings have impressed, unemployment remains at multi-decade lows and the economy is growing. So as we head into the seasonally strong fourth quarter, the question for anyone who still believes the broader trend is up becomes, "Which stocks are Wall Street analysts singling out as compelling investing opportunities?" We can use TipRanks to pinpoint top growth stocks - as identified by Wall Street's brightest minds - that have significant growth potential. Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
- GlobeNewswire•last month
Scilex Announces the Availability of ZTlido™
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (SRNE) (Sorrento), announced that ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is now commercially available. ZTLIDO will be shipped to wholesalers and is anticipated to be available by prescription at retail pharmacies across the U.S. by the end of this week, thus commencing a full U.S. launch. Scilex has entered into an agreement with Syneos Health (formerly, Inventiv Health) to support the launch and commercialization of ZTLIDO in the U.S. ZTLIDO is supported by an experienced, field sales team of over a hundred sales representatives, as well as Medical Science Liaison (MSL), market access and trade teams. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus which afflicts an estimated 1 million people each year in the US.
- GlobeNewswire•2 months ago
Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018
SAN DIEGO, Sept. 27, 2018-- Sorrento Therapeutics, Inc, a clinical stage, antibody-centric, biopharmaceutical company developing new therapies today announced that Henry Ji Ph.D,, Chairman, President and ...
- GlobeNewswire•2 months ago
Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus, which afflicts an estimated 1 million people each year in the US.
- GlobeNewswire•2 months ago
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
Sorrento Therapeutics, Inc. (SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), closed a debt financing with leading global institutional investors for aggregate gross proceeds to Scilex of $140 million. Scilex intends to use the net proceeds from this transaction for working capital and general corporate purposes in respect of commercialization of ZTlido™ (lidocaine topical system) 1.8%. Morgan Stanley & Co. LLC acted as sole structuring agent for the transaction. “This non-dilutive financing provides Scilex with the capital resources to successfully execute on the launch of ZTlido,” said Henry Ji, Chairman, President and Chief Executive Officer of Sorrento and Scilex.
- PR Newswire•2 months ago
Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation
- Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 - Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles ...
- GlobeNewswire•2 months ago
Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Sept. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)
SAN DIEGO, Sept. 02, 2018-- Sorrento Therapeutics, Inc., announced today that Dr. Henry Ji, Chairman and CEO, will be participating in upcoming investment healthcare conferences.. FB Riley Healthcare Conference ...
- Benzinga•3 months ago
Sorrento's Knee Pain Medication Found Safe, Effective Based On Early Data
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares were rallying Monday following the announcement of positive trial results for its osteoarthritis knee pain treatment candidate. In pre-market trading, the ...
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Sorrento Therapeutics
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Ampio Pharmaceuticals and Sorrento Therapeutics both saw big moves in opposite directions on Friday. Ampio Pharmaceuticals, Inc. shares closed up 11.44% on Friday with trading volume roughly three times higher than usual at 2,251,564 shares traded. It was recently revealed that Susquehanna International Group Llp has increased its position in the stock by $57,249.
- ACCESSWIRE•4 months ago
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
- Motley Fool•4 months ago
Why Clean Energy Fuels, Sorrento Therapeutics, and iQiyi Slumped Today
From an analyst downgrade to new tariffs on China, see why these three companies fell on Thursday.
- Motley Fool•4 months ago
Why Sorrento Therapeutics, Inc. Stock Sank Today
The biotech's share price dropped on no news -- but perhaps plenty of worries.
- ACCESSWIRE•5 months ago
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.
Reuters•5 months agoHong Kong market could open cash flood gates for U.S. biotechs
Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules. Striving to catch up with New York and Shanghai as an IPO hotspot, the Hong Kong Stock Exchange announced new policies late last year that actively court biotech companies, including those that do not have a drug on the market.
- Reuters•5 months ago
Hong Kong market could open cash flood gates for U.S. biotechs
When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent. Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules.
- ACCESSWIRE•6 months ago
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).
